Imunon opened higher at $0.76, compared with its previous close of $0.72. In the last trading session, the stock traded between $0.50 and $0.82. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Imunon is now worth
$ 2.77
Resulting in a loss of
$ 97.23 (97.23%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.06 (-8.21%)
Day High
$0.82
Day Low
$0.50
Day Open
$0.76
Prev Close
$0.72
Volume
21,42,388
1W Return
-27.12%
1M Return
-37.99%
3M Return
-59.22%
6M Return
-75.79%
1Y Return
-82.83%
Market Cap ($ Mn)
4
PE Ratio
-
PB Ratio
1.76
PEG Ratio
-
ROE
-391.76%
ROCE
-330.61%
EPS (TTM)
$-0.61
1 Week
-27.12%
1 Month
-37.99%
3 Months
-59.22%
6 Months
-75.79%
9 Months
-80.67%
Imunon Q3FY26 Results: Net loss widens 12% YoY to $3.8 million
Net loss widened 12% YoY to $3.8 million in Q3FY26. Cash position stands at $4.0 million with $5.0 million restricted. R&D expenses held steady at $1.8 million vs $1.9 million last year. Enrollment rate of 0.4 patients/site/month exceeds planning assumption. Sold ThermoDox rights for equity stake and potential milestones.
TodayImunon presents data showing IMNN-001 boosts T-cell immunity in ovarian cancer
Imunon Inc. presented translational data at SITC 2026 showing IMNN-001 increases CD8+/Treg and CD8+/CD4+ ratios in ovarian cancer tumors. The data provides an immunological mechanism for the 14.7-month improvement in median overall survival reported in the Phase 2 OVATION 2 study. Paired biopsies indicate IMNN-001 shifts the tumor microenvironment from immunologically cold to hot by activating T-cells and suppressing myeloid cells. The ongoing Phase 3 OVATION 3 trial aims to confirm these safety and survival benefits in a larger all-comers patient population.
6 days agoImunon sells ThermoDox rights to VoxelDox for up to $16.5M
Imunon sells ThermoDox rights to VoxelDox Therapeutics. Deal includes up to $16.5 million in milestone payments. Imunon retains equity stake and royalty rights. Move reinforces focus on Phase 3 OVATION 3 trial.
22 days agoImunon to host 2026 R&D day highlighting Phase 3 OVATION 3 trial
Imunon Inc. (NASDAQ: IMNN) will host its 2026 R&D Day on September 23, 2026, in New York City. The event will highlight progress in the Phase 3 OVATION 3 trial for IMNN-001, targeting advanced ovarian cancer. Updates will also cover the Phase 2 MRD trial conducted with Break Through Cancer and MD Anderson. A patient treated with IMNN-001 will share her firsthand perspective on the treatment journey.
2mo agoImunon Phase 3 Ovarian Cancer Trial Enrollment Surges Above Forecast
Imunon’s Phase 3 OVATION 3 trial for ovarian cancer is enrolling at 0.5 patients per site per month, well above the 0.3 planned rate and 0.2 industry average. Rapid site activation in 6 months supports a Q2 2029 enrollment completion target, driven by strong Phase 2 OS data.
3mo agoJeffrey Church retires as Imunon interim CFO effective July 1, 2026
Jeffrey Church retires as interim CFO of Imunon on July 1, 2026, succeeded by Josh Blacher. Church will continue as a consultant with a monthly retainer of $10,000.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Imunon is now worth
$ 2.77
Resulting in a loss of
$ 97.23 (97.23%)
Note: Past profits do not guarantee future returns.
